Janus Henderson Investors US’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
– Sell
-75,600
Closed -$5.76M – 1162
2016
Q4
$5.76M Sell
75,600
-36,300
-32% -$2.76M ﹤0.01% 819
2016
Q3
$9.33M Buy
111,900
+11,000
+11% +$922K 0.01% 707
2016
Q2
$8.32M Sell
100,900
-300
-0.3% -$24.7K 0.01% 693
2016
Q1
$7.68M Buy
101,200
+61,900
+158% +$4.58M 0.01% 705
2015
Q4
$3.16M Sell
39,300
-51,000
-56% -$3.68M ﹤0.01% 880
2015
Q3
$5.74M Buy
90,300
+14,200
+19% +$1.02M 0.01% 808
2015
Q2
$5.35M Buy
76,100
+51,500
+209% +$3.81M ﹤0.01% 790
2015
Q1
$1.95M Sell
24,600
-36,100
-59% -$2.66M ﹤0.01% 906
2014
Q4
$3.86M Buy
60,700
+8,800
+17% +$552K ﹤0.01% 837
2014
Q3
$3.1M Sell
51,900
-107,500
-67% -$6.15M ﹤0.01% 855
2014
Q2
$8.53M Buy
159,400
+79,700
+100% +$4.37M 0.01% 704
2014
Q1
$4.81M Buy
+79,700
New +$4.65M ﹤0.01% 776
2013
Q4
– Sell
-6,300
Closed -$291K – 1078
2013
Q3
$291K Sell
6,300
-64,400
-91% -$2.96M ﹤0.01% 1029
2013
Q2
$2.9M Buy
+70,700
New +$3.03M ﹤0.01% 781

Other funds holding CRL

Janus Henderson Investors US's CRL Position: Q1 2017 in Review

Janus Henderson Investors US sold out of Charles River Laboratories (CRL) in Q1 2017, closing a stake of 75,600 shares — an estimated $5.76M sold.

Janus Henderson Investors US first reported a position in CRL in Q2 2013 and held it in 14 quarters. The position peaked at $9.33M in Q3 2016. 300 funds tracked by Wall St. Rank hold CRL as of Q1 2017.

  • Janus Henderson Investors US reported no remaining Charles River Laboratories position as of Q1 2017 after selling out during the quarter.
  • Janus Henderson Investors US sold 75,600 Charles River Laboratories shares in Q1 2017, an estimated $5.76M.
  • Janus Henderson Investors US first reported a position in Charles River Laboratories in Q2 2013 and held it in 14 quarters.
  • Janus Henderson Investors US's Charles River Laboratories position peaked at $9.33M in Q3 2016.
  • 300 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.